Guillain-Barre syndrome in a patient with diffuse large B-cell lymphoma, and rituximab maintenance therapy. An association beyound anecdotal evidence?

Clinical and Translational Oncology

Volumn 8, Issue 10, 2006, Pages 764-766

  Carmona, Alberto ^a   Alonso, Juan Domingo ^a   de las Heras, Manuel ^a   Navarrete, Agustín ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

Cancer; Guilain Barre syndrome; Lymphoma; Maintenance; Paraneoplastic syndromes; Polyneuropathy; Rituximab

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IMMUNOGLOBULIN; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; CHOP PROTOCOL; MONOCLONAL ANTIBODY;

ADULT; ANAMNESIS; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; DISEASE ASSOCIATION; GUILLAIN BARRE SYNDROME; HUMAN; LARGE CELL LYMPHOMA; LIMB WEAKNESS; MAINTENANCE THERAPY; MALE; PARANEOPLASTIC NEUROPATHY; PLASMA CELL; COMPARATIVE STUDY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PARANEOPLASTIC SYNDROME; RADIATION DOSE; RECURRENT DISEASE; REMISSION; SPLENECTOMY; TIME; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PARANEOPLASTIC SYNDROMES; PREDNISONE; RADIOTHERAPY DOSAGE; RECURRENCE; REMISSION INDUCTION; SPLENECTOMY; TIME FACTORS; TREATMENT OUTCOME; VINCRISTINE;

EID: 34250196647     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-006-0126-5     Document Type: Article

References (28)

1. Vedeler CA. Inflammatory neuropathy: Update. Curr Opin Neurol. 2000;13:305-9.
2. Asbury A, Arnason BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. Medicine. 1969;48:173-215.
3. Hadden RD, Cornblath DR, Hughes RA, et al. Electrophysiological classification of Guilain-Barre syndrome: Clinical associations and outcome. Ann Neurol. 1998;44:780-8.
4. Hafer-Macko C, Hsieh ST, Li GY, et al. Acute motor axonal neuropathy: An antibody-mediated attack on axolemma. Ann Neurol. 1996;40:655-44.
5. Winer JB, Kangro RA, Anderson MJ, Jones DM, Kangro H, Watkins RP. A prospective study of acute idiopathic neuropathy. II. Antecedent events. J Neurol Neurosurg Psychiatry. 1988;51:613-8.
6. Hahn AF. Guillatin-Barre syndrome. Lancet. 1998;352(9128):635-41.
7. Waksman, BH, Adams RD. Allergic neuritis: An experimental disease of rabbits induced by the injection of peripheral nervous tissue and adjuvants. J Exp Med. 1955;102:213.
8. Vigliani MC, Magistrello M, Polo P, Mutani R, Chio A. Risk of cancer in patients with Guillain-Barre syndrome (GBS). A population-based study. Piemonte and Valle d'Aosta Register for Guillain-Barre Syndrome. J Neurol. 2004;25(3):321-6.
9. Zuk E, Nowacki P, Fabian A. Guillain-Barre syndrome in patient with Burkitt's lymphoma and type 2 diabetes mellitus. Folia Neuropathol. 2001;39(4):281-4.
10. Toren A, Mandel M, Shahar E, Rimmoni E. Primary central newrvous system Burkitt's lymphoma presenting as Guillain-Barre syndrome. Med Pediatr Oncol. 1994;25(4):372-5.
11. Phan TG, Manoharan A, Pryor D. Relapse of central nervous system Burkitt's lymphoma presenting as Guillain-Barre syndrome and syndrome of inappropriate ADH secretion. Aust N Z J Med. 1998;28(2):223-4.
12. Magne N, Foa C, Castadot P, Ott J. Guillain-Barre syndrome and non-Hodgkin's lymphoma. Report of one case and review of literature. Rev Med Brux. 2005;26(2):108-11.
13. Rees JH, Thompson RD, Smeeton NC, Hughes RA. Epidemiological study of Guillain-Barre syndrome in South East England. J Neurol Neurosurg Psychiatry. 1998;64:74-7.
14. Jacobs BC, O'Hanlon GM, Bullens RW, Veitch J, Plomp JJ, Willison HJ. Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain. 2003;126(Pt 10):2220-34.
15. Buchwald B, Ahangari R, Weishaupt A, Toyka KV. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barre syndrome. Ann Neurol. 2002;51(6):673-80.
16. Kuwabara S. Guillain-Barre syndrome: Epidemiology, pathophysiology and management. Drugs. 2004;64:597-610.
17. Radhakrishnan VV, Sumi MG, Reuben S, Mathai A, Nair MD. Serum tumour necrosis factor-alpha and soluble tumour necrossi factor receptors levels in patients with Guillain-Barre syndrome. Acta Neurol Scand. 2004;109:71-4.
18. Bubien JK, Zhou LJ, Bell PD, Frizzell RA, Tedder TF. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2++ conductance found constitutively in B-lymphocytes. J Cell Biol. 1993;121:1121-32.
19. Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab. Neurology. 1999;52:1701-4.
20. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse/human monoclonal antibody to CD20. Blood 1994;83:435-45.
21. Finsterer J. Treatment of immune-mediated, dysimmune neuropathies. Acta Neurol Scand. 2005;112(2):115-25.
22. Lunenmann JD, Prass K, Zschenderlein R. Immunotherapy of chronic inflammatory demyelinating polyneuropathy. Fortschr Neurol Psychiatr. 2004;72:672-8.
23. Ruegg SJ, Fuhr P, Steck AJ. Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg. Neurology. 2004;63:2178-9.
24. Alwayn IP, Xu Y, Basker M, et al. Effects of specific anti-B and/or anti-plasma cell immunogherapy on antibody production in baboons: depletion of CD20- and CD22- positive B cells does not result in significantly decreased production of anti-alphaGal antibody. Xenotransplantation. 2001;8:157-71.
25. Rojas-García R, Gallardo E, de Andrés I, de Luna N, Juárez C, Sanchez P, Illa I. Chronic neuropathy with IgM anti-ganglioside antibodies: Lack of long term response to rituximab. Neurology. 2003;61(12):1814-6.
26. Ghobrial IM, Fonseca R, Greipp PR, et al. Eastern Cooperative Oncology Group: Initial immunoglobulin M ≪flare" after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia - An Eastern Cooperative Oncology Group study. Cancer. 2004:101:2593-8.
27. Vanita Noronha, Thomas M. Fynan, Thomas Duffy. Flare in Neuropathy Following Rituximab Therapy for Waldenstrom's Macroglobulinemia JCO. 2006:e3.
28. Buda-Okreglak EM, Drabick JJ, Delaney NR. Proinflammatory syndrome mimicking acute rheumatoid arthritis in a patient with Waldenstrom's macroglobulinemia treated with rituximab. Ann Hematol. 2004;83:117-9.